MIDOSTAURIN

Basic Information

Item Value
DrugBank ID DB06595
Evidence Level L5 (Computational Prediction)
Number of Predicted Indications 21

Predicted Indications (TxGNN)

The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.

# Indication Source
1 acute myeloblastic leukemia with maturation TxGNN Knowledge Graph
2 acute myeloblastic leukemia without maturation TxGNN Knowledge Graph
3 acute myeloid leukemia with inv3(p21;q26.2) or t(3;3)(p21;q26.2) TxGNN Knowledge Graph
4 acute myeloid leukemia with t(8;16)(p11;p13) translocation TxGNN Knowledge Graph
5 acute myeloid leukemia with CEBPA somatic mutations TxGNN Knowledge Graph
6 therapy related acute myeloid leukemia and myelodysplastic syndrome TxGNN Knowledge Graph
7 acute myeloid leukemia and myelodysplastic syndromes related to topoisomerase type 2 inhibitor TxGNN Knowledge Graph
8 aleukemic mast cell leukemia TxGNN Knowledge Graph
9 unclassified acute myeloid leukemia TxGNN Knowledge Graph
10 aggressive systemic mastocytosis TxGNN Knowledge Graph
11 acute myeloid leukemia with minimal differentiation TxGNN Knowledge Graph
12 mastocytosis TxGNN Knowledge Graph
13 acute myeloid leukemia with t(8;21)(q22;q22) translocation TxGNN Knowledge Graph
14 acute myeloid leukemia with t(6;9)(p23;q34) TxGNN Knowledge Graph
15 inherited acute myeloid leukemia TxGNN Knowledge Graph
16 mast cell leukemia TxGNN Knowledge Graph
17 acute myeloid leukemia with t(9;11)(p22;q23) TxGNN Knowledge Graph
18 systemic mastocytosis TxGNN Knowledge Graph
19 myeloid leukemia TxGNN Knowledge Graph
20 obsolete classic mast cell leukemia TxGNN Knowledge Graph
21 acute myeloid leukemia with NPM1 somatic mutations TxGNN Knowledge Graph

Disclaimer

These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.


← Back to Drug Search